

# Systemic Rheumatic Diseases

Rachel M. Wolfe

Andrew C. Seymore

R. Darrell Nelson

## REFERENCES

1. Slobodin G, Hussein A, Rozenbaum M, Rosner I: The emergency room in systemic rheumatic diseases. *Emerg Med J* 23: 667, 2006. [PMID: 16921075]
2. Gutiérrez-González LA: Rheumatologic emergencies. *Clin Rheumatol* 34: 2011, 2015. [PMID: 26099604]
3. Janssen NM, Karna DR: Rheumatologic diseases in the intensive care unit: epidemiology, clinical approach, management, and outcome. *Crit Care Clin* 18: 729, 2002. [PMID: 12418438]
4. Abe K, Mitsuka T, Yamaoka A: Sudden glottic stenosis caused by cricoarytenoid joint involvement due to rheumatoid arthritis. *Intern Med* 52: 2469, 2013. [PMID: 24190155]
5. Papiris SA, Manali ED, Kolilekas L, et al: Acute respiratory events in connective tissue disorders. *Respiration* 91: 181, 2016. [PMID: 26938462]
6. Woodhead F, Wells AU, Desai SR: Pulmonary complications of connective tissue diseases. *Clin Chest Med* 29: 149, 2008. [PMID: 18267189]
7. Luppino-Assad AP, Gavilanes-Oleas F, Alves JL, et al: Survival of connective tissue disease associated pulmonary arterial hypertension. *Clin Exp Rheumatol* 113: 36, 2018. [PMID: 16218473]
8. Holmqvist ME, Neovius M, Eriksson J, et al: Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. *JAMA* 379: 244, 2012.
9. Zoller B, Li X, Sundquist J, Sundquist K: Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up from Sweden. *Lancet* 11: 61306, 2011. [PMID: 22119579]
10. Conway R, Low C, Coughlan RJ, et al: Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. *Arthritis Rheumatol* 66: 803, 2014. [PMID: 24757133]
11. de Prost N, Parrot A, Picard C, et al: Diffuse alveolar hemorrhage: factors associated with in-hospital and long-term mortality. *Eur Respir J* 55: 1303, 2010. [PMID: 19840965]
12. Rabe C, Appenrodt B, Hoff C, et al: Severe respiratory failure due to diffuse alveolar hemorrhage: clinical characteristics and outcome of intensive care. *J Crit Care* 25: 230, 2010. [PMID: 19592204]
13. de prost N, Parrot A, Cuquemelle E, et al: Diffuse alveolar hemorrhage in immunocompetent patients: etiologies and prognosis revisited. *Respir Med* 106: 1021, 2012. [PMID: 22541718]
14. Martínez-Martínez MU, Oostdam DAH, Abud-Mendoza C: Diffuse alveolar hemorrhage in autoimmune diseases. *Curr Rheumatol Rep* 19: 27, 2017. [PMID: 28397125]
15. Ednalino C, Yip J, Carsons SE: Systematic review of diffuse alveolar hemorrhage in systemic lupus erythematosus: focus on outcome and therapy. *J Clin Rheumatol* 21: 305, 2015. [PMID: 26308350]
16. Güngör G, Tatar D, Saltürk C, et al: Why do patients with interstitial lung diseases fail in the ICU? A 2-center cohort study. *Respir Care* 58: 525, 2013. [PMID: 23443285]
17. Wallace B, Yummidhi D, Khanna D: Management of connective tissue diseases associated interstitial lung disease: a review of the published literature. *Curr Opin Rheumatol* 28: 236, 2016. [PMID: 27027811]
18. Savale L, Weatherer J, Jais X, et al: Acute decompensated pulmonary hypertension. *Eur Respir Rev* 26: 170092, 2017.
19. Gargiulo P, Marsico F, Parente A, et al: Ischemic heart disease in systemic inflammatory diseases. An appraisal. *Int J Cardiol* 170: 286, 2014. [PMID: 24331863]
20. Schoenfeld SR, Kasturi S, Costenbader KH: The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. *Semin Arthritis Rheum* 43: 77, 2013. [PMID: 23422269]
21. Holmqvist M, Ljung L, Askling J: Acute coronary syndrome in new-onset rheumatoid arthritis: a population-based nationwide cohort study of time trends in risks and excess risks. *Ann Rheum Dis* 76: 1642, 2017. [PMID: 28710095]
22. Hahn BH, Grossman J, Chen W, McMahon M: The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. *J Autoimmun* 28: 69, 2007. [PMID: 17433865]
23. Maradit-Kremers H, Crowson CS, Nicola PJ, et al: Increased unrecognized coronary artery disease and sudden deaths in rheumatoid arthritis. *Arthritis Rheum* 52: 402, 2005. [PMID: 15693010]
24. Lazarini PE, Capocchi PL, Guideri R, et al: Connective tissue diseases and cardiac rhythm disorders: an overview. *Autoimm Rev* 5: 306, 2006.
25. van Halm VP, Peters MJL, Voskuyl AE, et al: Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. *Ann Rheum Dis* 68: 1398, 2009.
26. Lindhardsen J, Ahlehoff O, Gislason GH, et al: Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study. *BMJ* 344: 1257, 2012. [PMID: 224032W67]
27. Watad A, Tiosano S, Grysman N, et al: The association between systemic lupus erythematosus and valvular heart disease: an extensive data analysis. *Eur J Clin Invest* 47: 366, 2017. [PMID: 28295225]
28. Fei Y, Li X, Lin S, et al: Major vascular involvement in Behcet's disease: a retrospective study of 796 patients. *Clin Rheumatol* 32: 845, 2013. [PMID: 23443336]
29. Hatemi G, Christensen R, Bang D, et al: 2018 update of the EULAR recommendations for the management of Behcet's syndrome. *Ann Rheum Dis* 77: 808, 2018. [PMID: 29625968]
30. Ahn JK, Lee YS, Jeon CH, et al: Treatment of venous thrombosis associated with Behcet's disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. *Clin Rheumatol* 27: 201, 2008. [PMID: 17636362]
31. Tayar-Shifman OE, Seyahi E, Nowatzky J, Ben-Chetrit E: Major vessel thrombosis in Behcet's disease: the dilemma of antiocoagulant therapy—the approach of rheumatologists from different countries. *Clin Exp Rheumatol* 30: 735, 2012. [PMID: 22703971]
32. Kalra S, Silman A, Akman-Demir G, et al: Diagnosis and management of Neuro-Behcet's disease: international consensus recommendations. *J Neurol* 261: 1662, 2014. [PMID: 24366648]
33. Cervera R, Rodriguez-Pinto I, Espinosa G: The diagnosis and clinical management of catastrophic antiphospholipid syndrome: a comprehensive review. *J Autoimmun* 92: 1, 2018. [PMID: 29779928]
34. Bucciarelli S, Erkan D, Espinosa G, et al: Catastrophic antiphospholipid syndrome: treatment, prognosis, and the risk of relapse. *Clin Rev Allergy Immunol* 36: 80, 2009. [PMID: 19051065]
35. Ruffatti A, De Silvestro G, Marson P, et al: Catastrophic antiphospholipid syndrome: Lessons from 14 cases successfully treated in a single center. *J Autoimmun* 93:124, 2018. [PMID: 30146007]
36. Leker RR: Stroke complicating systemic immune mediated disorders. *Semin Cerebrovasc Dis Stroke* 5: 21, 2005.
37. Chen X, Xu G: Intravenous thrombolysis in SLE-related stroke: a case report and literature review. *Neurol Sci* 39: 155, 2018. [PMID: 29116545]
38. Loharia JJ, Alam JM, Abdelhadi HA, Marei TF: Thrombolytic therapy at systemic lupus onset with secondary antiphospholipid syndrome. A rare stroke experience. *Neurosciences (Riyadh)* 20: 55, 2015. [PMID: 25630783]
39. Majdak MR, Vučetić V: Thrombolysis for acute stroke in patient with systemic lupus erythematosus: a case report. *J Neurol Sci* 15: 7, 2016.
40. Stadler K, Mutzenbach JS, Kals G, et al: Therapeutic challenges after successful thrombectomy in a patient with an antiphospholipid syndrome associated M1-occlusion: a case report. *Interv Neuroradiol* 21: 598, 2015. [PMID: 26135672]
41. Fattah P, Sheriff F, Narayanan NS, et al: Thrombolysis for acute stroke in patients with vasculitis: case report and literature discussion. *Clin Neurol Neurosurg* 115: 351, 2013. [PMID: 22717602]
42. Gopalakrishnan S, Cynthia B, Roth Sanford I, et al: Unsuspected vasculitis and intracranial hemorrhage following thrombolysis. *Clin Cardiol* 20: 84, 1997.
43. Strangfeld A, Listing J, Herzer P, et al: Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-α agents. *JAMA* 301: 737, 2009. [PMID: 19224750]
44. Forbes HJ, Bhaskaran K, Thomas SL, et al: Quantification of risk factors for herpes zoster: population based case-control study. *BMJ* 348: 2911, 2014. [PMID: 25134101]
45. Lukasiewicz AM, Bohl DD, Varthi AG, et al: Spinal fracture in patients with ankylosing spondylitis. *Spine* 41: 191, 2017.
46. West TW: Transverse myelitis: a review of the presentation, diagnosis, and initial management. *Discov Med* 16: 167, 2013. [PMID: 24099672]
47. Berkowitz AL, Samuels MA: The neurology of Sjögren's syndrome and the rheumatology of peripheral neuropathy and myelitis. *Pract Neurol* 14: 14, 2014. [PMID: 24307005]
48. Nardone R, Fitzgerald RT, Bailey A, Zuccoli G: Longitudinally extensive transverse myelitis in systemic lupus erythematosus: case report and review of the literature. *Clin Neurol Neurosurg* 129: 57, 2015. [PMID: 25544684]
49. Foster CS: Ocular manifestations of the potentially lethal rheumatologic and vasculitic disorders. *J Fr Ophthalmol* 36: 526, 2013. [PMID: 23688612]
50. Lichtenstein SJ, Herring MJ, Baxi PV, et al: Without warning: scleroderma renal crisis. *Am J Med* 132: 175, 2019. [PMID: 30290189]
51. Zanatta E, Polito P, Favaro M, et al: Therapy of scleroderma renal crisis: state of the art. *Autoimmun Rev* 17: 882, 2018. [PMID: 30005860]
52. Yuan S, Ye Y, Chen D, et al: Lupus mesenteric vasculitis: clinical features and associated factors for the recurrence and prognosis of disease. *Semin Arthritis Rheum* 43: 759, 2014. [PMID: 24332116]
53. Ospina FE, Echeverri A, Zambrano D, et al: Distinguishing infections vs flares in patients with systemic lupus erythematosus. *Rheumatology (Oxford)* 56: i46, 2017. [PMID: 27744359]
54. Wu JY, Lee SH, Shen CJ, et al: Use of serum procalcitonin to detect bacterial infection in patients with autoimmune diseases: a systematic review and meta-analysis. *Arthritis Rheum* 64: 3034, 2012. [PMID: 22605405]
55. Song GG, Bae SC, Lee YH: Diagnostic accuracies of procalcitonin and C-reactive protein for bacterial infection in patients with systemic rheumatic diseases: a meta-analysis. *Clin Exp Rheumatol* 33: 166, 2015. [PMID: 25602442]
56. Galloway JB, Hyrich KL, Mercer LK, et al: Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. *Rheumatology* 50: 124, 2011. [PMID: 20675706]
57. Salar O, Baker B, Kurien T, et al: Septic arthritis in the era of immunosuppressive treatments. *Ann R Coll Surg Engl* 96: e11, 2014. [PMID: 24780657]
58. Rhen T, Cidlowski JA: Anti-inflammatory action of glucocorticoids-new mechanisms for old drugs. *N Engl J Med* 353: 1711, 2005. [PMID: 16236742]
59. Linnemann B, Erbe M: Raynaud's phenomenon and digital ischaemia: pharmacologic approach and alternative treatment options. *Vasa* 45: 201, 2016. [PMID: 27129065]

60. Herrick AL: Evidenced-based management of Raynaud's phenomenon. *Ther Adv Musculoskel Dis* 9: 317, 2017. [PMID: 29201156]
61. Van Vollenhoven RF, Emery P, Bingham CO III, et al: Long-term safety of patients receiving rituximab in rheumatoid arthritis clinical trials. *J Rheumatol* 37: 558, 2010. [PMID: 20110520]
62. Safa G, Darrieux L: Cerebral toxoplasmosis after rituximab therapy. *JAMA Intern Med* 173: 924, 2013. [PMID: 23589123]
63. Kelesidis T, Daikos G, Boumpas D, Tsiodras S: Does rituximab increase the incidence of infectious complications? A narrative review. *Int J Infect Dis* 15: 2, 2011. [PMID: 21074471]
64. Merrill JT, Ginzler EM, Wallace DJ, et al: Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. *Arthritis Rheum* 64: 3364, 2012. [PMID: 22674457]
65. Salliot C, Dougados M, Gossec L: Risk of serious infections during rituximab, abatacept, and anakinra treatments for rheumatoid arthritis: meta-analyses of randomized, placebo-controlled trials. *Ann Rheum Dis* 68: 25, 2009. [PMID: 18203761]
66. Major EO: Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. *Ann Rev Med* 61: 35, 2010. [PMID: 19719397]
67. Wallace DJ, Gudsoorkar VS, Weisman MH, et al: New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. *Nat Rev Rheumatol* 8: 522, 2012. [PMID: 22801982]
68. Mosak J, Furie R: Comparative safety of therapies in systemic lupus erythematosus. *Rheum Dis Clin North Am* 38: 795, 2012. [PMID: 23137583]
69. Sakuma Y, Katoh T, Owada K, et al: Initial functional status predicts infections during steroid therapy for renal diseases. *Clin Nephrol* 63: 68, 2005. [PMID: 15730047]
70. Wolfe F, Caplan L, Michaud K: Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, DMARDs, and anti-tumor necrosis factor therapy. *Arthritis Rheum* 54: 628, 2006. [PMID: 16447241]